KS

Kiersten Stead

Managing Partner at DCVC Bio

San Francisco, California

Overview

Work Experience

NT

Nilo Therapeutics

  • Board Member

    2024 - Current

RO

Radionetics Oncology

  • Board Member

    2024

LB

Latus Bio

  • Board Member

    2024

TM

Totus Medicines

  • Board Member

    2024

M

Mycoworks

  • Board Member

    2019

ST

Stemson Therapeutics

  • Board Member

    2021

DB

DCVC Bio

  • Managing Partner

    2018

    Managing Partner DCVC Bio

EL

Elo Life Systems

  • Board Member

    2022 - 2024

CB

Creyon Bio

  • Board Member

    2021 - 2024

Education

Investments

Latus Bio

Series A

Total Funding: $54M

Elo Life Systems

Series A

Total Funding: $21M

Totus Medicines

Series B

Total Funding: $110M

Novome Biotechnologies

Series A

Total Funding: $82M

Relevant Websites